BioRestorative Therapies Inc. Common Stock (NV) (BRTX)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that can earn durable returns on capital and defend themselves. BioRestorative Therapies does not yet look like that. It has a scientific story: BRTX-100, an autologous cultured mesenchymal stem cell therapy for disc/spine disease and metabolic disorders, run by only 13 employees. But a story is not a moat. In fiscal 2025, the year ended 2025-12-31, revenue was $359,700 and net loss was $14.2 million. In fiscal 2024, the year ended 2024-12-31, revenue was $401,000 and net loss was $9.0 million. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $23,170 and net loss was $2.2 million. Trailing free cash flow is negative $11.9 million, a -29.4% FCF yield against the $40.5 million market cap. That is not owner earnings; it is capital consumption. The balance sheet has little debt—D/E 0.01—which helps. But FairStock's Altman Z-score of -38.70 and Piotroski F-score of 3/9 signal financial fragility. The FairStock P/B of 0.67 at the 2026-10-13 close might tempt a Graham investor, but book value here is not supported by earning power; FairStock's P/E is -0.08, and FairStock assigns no Peter Lynch category because the company lost money in each of the last four years. At the close on 2026-10-13, the price was $1.59, within a 52-week range of $0.14 to $2.93. Growth? Revenue is tiny, and FairStock's revenue-growth metric is -7.32%. FairStock's profit-growth figure of 59.65% is not enough to offset annual losses and cash burn. I would need clinical validation, meaningful sales, and a clearer path to self-funding before calling this a value opportunity. Until then, it is speculation, not investment.

In plain English: BioRestorative Therapies is a small biotech with 13 employees trying to develop stem-cell treatments for back/spine and metabolic problems. It has almost no sales, loses millions each year, and burns cash. The stock price looks low, but against its tiny revenue and continuing losses it does not look like a proven bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer